Acadia's $30 Million DAYBUE Guide Is the Real Call Option on remlifanserin

DAYBUE validated the commercial engine, but remlifanserin still drives the upside

The market is acting as though DAYBUE proved Acadia can execute, while remlifanserin may decide how high the stock goes. That is the core tension. Once a biotech company proves a commercial asset is working, investors do not only pay for the revenue; they also pay for what that revenue suggests about the rest of the franchise. DAYBUE has done that. Q2 DAYBUE net sales reached $125 million, and Acadia raised full-year 2026 total revenue guidance to $1.24 billion to $1.30 billion. Even so, the shares remained near the $28.35 52-week high after earnings.

That is where the debate splits. Bulls see a validated commercial engine that lowers execution risk and makes the pipeline more valuable. Bears see a story that may be getting ahead of itself: once DAYBUE impressed, management's approximately $1.7 billion in projected 2028 net sales outlook started to sound less like ambition and more like a base case. The risk for late buyers is that the market is valuing Acadia as a two-asset company before remlifanserin has cleared that hurdle. If the Phase 2 data land well, the rerating could accelerate. If they disappoint, the stock could quickly revert from a two-asset story back to a one-asset company carrying high expectations.

The raised DAYBUE forecast matters because it tightens the demand story

The raised DAYBUE outlook matters because it moves the discussion past a single launch quarter and toward a more credible demand curve. Earlier this year, management anchored the long-range case to approximately $1.7 billion in global projected net sales by 2028, with roughly $1 billion for NUPLAZID and roughly $700 million for DAYBUE, while DAYBUE STIX was scheduled for a limited U.S. launch in Q1 2026 and a broader launch in Q2 2026. Against that backdrop, one strong quarter could have been written off as launch noise. A higher full-year range is harder to dismiss.

The forecast is now more specific, so the commercial case is easier to underwrite

DAYBUE produced $125 million in Q2 GAAP net sales, up 30% year over year, and management lifted full-year DAYBUE guidance to $480 million to $510 million. That matters because investors no longer have to infer DAYBUE's contribution from a broader revenue figure. They can now anchor to a narrower, more recent forecast for the newer asset.

That also makes the commercial leg of the story feel more like an observed trend than a one-quarter headline. Bulls had argued DAYBUE could scale beyond the initial launch burst; management has now supplied a second evidence point that supports that view.

NUPLAZID keeps the base diversified

NUPLAZID is what keeps Acadia's commercial foundation from looking one-dimensional. In the second quarter, NUPLAZID generated $183 million in GAAP net sales, up 10% year over year on a non-GAAP adjusted basis, and management reaffirmed full-year guidance at $760 million to $790 million. That does not make remlifanserin less important. It changes how investors may price it.

When both franchises are tracking well, pipeline optionality is easier to underwrite. Remlifanserin starts to look more like upside layered on a sturdier base, not a rescue bet carried by a single asset. Commercial strength improves the setup; it does not remove the need for remlifanserin to work.

Remlifanserin data in September-October remain the key repricing event

The next major repricing event is not another solid DAYBUE quarter. It is whether remlifanserin can push investors to value Acadia as more than a two-product company. That window is now close, with RADIANT Phase 2 topline results anticipated between August and October 2026. Management has described the readout as a potentially transformational opportunity, which is another reason the commercial base matters now: investors no longer need to excuse pipeline uncertainty on survival grounds.

What could change when the data arrive

If remlifanserin shows a credible signal in Alzheimer's disease psychosis, the market may become more willing to value Acadia on a broader neuroscience franchise rather than only on NUPLAZID and DAYBUE. That is the bull case in plain terms: commercial execution is already visible, so positive pipeline data could unlock a higher valuation multiple.

The bear case is simpler. A stronger commercial base raises expectations. If investors feel more protected by present-tense sales, they may become less willing to quietly underwrite remlifanserin at a steep discount. In that setting, disappointing data could hurt precisely because the market has less reason to look away.

Three watchpoints into the readout

• DAYBUE run rate: the new $480 million to $510 million guide implies roughly $120 million to $127.5 million per quarter, so investors will look for the launch trend to stay intact.
• NUPLAZID durability: continued growth in NUPLAZID matters because it keeps Acadia's base diversified and less dependent on a single winner.
• remlifanserin proof: the August-to-October RADIANT readout is the event that could shift Acadia from a strong commercial story to a broader pipeline story.

That is the real setup. DAYBUE has strengthened the base case, but remlifanserin is still the asset most likely to reset expectations.